Chemoswed AB

"when good enough isn't"

Chemoswed is your ideal partner in producing active pharmaceutical ingredients.

Chemoswed’s cGMP approved and FDA inspected facilities offer all the analytical and production capabilities you need for APIs, including:

  • Lab/Kilolab/Pilot/Production scale facilities
  • Process and analytical development
  • High potent/oncology containment capabilities
  • Regulatory assistance
  • Reliable, efficient and on-time

Chemoswed is the reliable Swedish custom synthesis specialist, supplying active ingredients since 1944. With a background in Pharmacia, Chemoswed offers cost-effective solutions to API needs worldwide.

We have established unparalleled experience and technology, enabling efficient development and production of quality active pharmaceutical ingredients in quantities from 100 grams to 50 tons.

Our dedicated personnel are experts in process development, scale–up, analytical chemistry, as well as regulatory and technical challenges. We operate in meticulously maintained facilities, comprising a kilolab, and pilot and commercial production plants, with more than 30 m3 reactor capacity.

Our clients represent a global mix of biotech companies and large pharmaceutical corporations.

Cost-effective operations and services are ensured through an in–depth knowledge of most areas of drug development and regulatory aspects, as well as an extensive professional network providing relevant, associated services. We maintain an excellent authority (USFDA, EMA, SMPA) inspection track record, and up–to–date cGMP compliance.

One of our key specialities is the handling of highly potent compounds in fully-contained manufacturing suites.

 

 

 

 

 

 

At Chemoswed, we place special emphasis on customer communication and project documentation. We strive to provide maximal transparency and foster an informal project management culture, encouraging multi–level interactions. Succinct reporting by way of weekly summaries are complemented by lucid reports and frequent teleconferences.